Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.
A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.
At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.
The 24-month follow-up of the phase 1/2 CheckMate 358 trial found nivolumab with or without ipilimumab yielded clinically meaningful, long-lasting responses in patients with recurrent or metastatic cervical cancer.
In a population of patients with cervical intraepithelial neoplasia and stage IA1 cervical cancer, certain local treatments, such as radical excision and ablation, were associated with treatment outcomes and risk of preterm birth.
Investigators reported that vaccinated patients had a higher rate of grade 2/3 cervical neoplasia due to non–vaccine preventable human papillomavirus compared with unvaccinated patients, an event commonly termed clinical unmasking.
Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.
Patients with advanced newly diagnosed ovarian, tubal, or peritoneal cancer did not derive further survival benefit from maintenance chemotherapy, although a modest improvement in progression-free survival was observed compared with surveillance.
Nutritional markers such as body mass index, weight loss, and albumin should be assessed to identify pre-operative malnutrition in patients with gynecologic cancers.
Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.